EUVIMEDEUVIMED entdecken
Crossref

Evaluating the Impact of Linezolid Metabolites: PNU‐142300 and PNU‐142586 on the Development of Linezolid‐Induced Thrombocytopenia in Adult Patients

Norihiro Sakurai iD, Hiroshi Kawaguchi, Toya Matsui, Hironobu Nishiura, Kazuhiro Kobayashi, Waki Imoto, Wataru Shibata, Yasutaka Nakamura, Hiroshi Kakeya

The Journal of Clinical Pharmacology · 2025

DOI: 10.1002/jcph.70124 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Norihiro Sakurai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Abeno-ku, Osaka, Japan. Hauptthemen laut MEDLINE: Linezolid, Thrombocytopenia, Anti-Bacterial Agents. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Linezolid is a widely used antimicrobial agent in clinical practice; however, its usage is often limited by linezolid‐induced thrombocytopenia (LIT). While prior studies have assessed linezolid plasma concentrations, the clinical relevance of its metabolites, PNU‐142300 and PNU‐142586, remains unclear. This study aimed to investigate the association between these metabolite concentrations and LIT, and to identify predictive thresholds. This study retrospectively analyzed patients treated with linezolid at Osaka Metropolitan University Hospital between January 2017 and December 2024. Patient characteristics, trough concentrations (C trough ), AUC 24 , and pharmacokinetic parameters of linezolid and its metabolites were compared among patients with and without thrombocytopenia. Receiver operating characteristic (ROC) analysis identified thresholds for LIT prediction. Risk factors were assessed using multivariate logistic regression analysis. Forty‐eight patients were included, with thrombocytopenia developing in 26 patients (54.2%). C trough and AUC 24 of PNU‐142300 and PNU‐142586 were significantly higher in the thrombocytopenia group; meanwhile, linezolid C trough and AUC 24 did not differ significantly. ROC analysis identified C trough ≥1.43 µg/mL and AUC 24 ≥37.8 mg h/L for PNU‐142586 as predictive thresholds. Multivariate analysis revealed that linezolid therapy ≥14 days (OR = 9.53, P = .044) and PNU‐142586 C trough ≥1.43 µg/mL (OR = 37.60, P = .002) as independent risk factors. Elevated PNU‐142586 concentrations were associated with a higher cumulative incidence of LIT. Accumulation of linezolid metabolites, especially PNU‐142586, is closely associated with LIT. Monitoring of PNU‐142586 may improve the safety of linezolid therapy and support individualized dosing strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LinezolidThrombocytopeniaAnti-Bacterial AgentsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedAdultRisk FactorsAged, 80 and over

Stichwörter der Autor:innen

PNU‐123400PNU‐142586linezolidthrombocytopenia

Substanzen

LinezolidAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Abeno-ku, Osaka, Japan.
  • Department of Pharmacy, Osaka Metropolitan University Hospital, Abeno-ku, Osaka, Japan.
  • Department of Infection Control, Osaka Metropolitan University Hospital, Abeno-ku, Osaka, Japan.
  • Department of Pharmacy, Tazuke Kofukai Medical Research Institute, Kitano Hospital, Kita-ku, Osaka, Japan.
  • Research Center for Infectious Disease Sciences (RCIDS), Osaka Metropolitan University Graduate School of Medicine, Abeno-ku, Osaka, Japan.
  • Osaka International Research Center for Infectious Diseases (OIRCID), Osaka Metropolitan University, Abeno-ku, Osaka, Japan.

ORCID-Profile: Norihiro Sakurai

Zitieren

APA

Sakurai, N., Kawaguchi, H., Matsui, T., Nishiura, H., Kobayashi, K., Imoto, W., Shibata, W., Nakamura, Y., & Kakeya, H. (2025). Evaluating the Impact of Linezolid Metabolites: PNU‐142300 and PNU‐142586 on the Development of Linezolid‐Induced Thrombocytopenia in Adult Patients. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70124

Vancouver

Sakurai N, Kawaguchi H, Matsui T, Nishiura H, Kobayashi K, Imoto W, et al. Evaluating the Impact of Linezolid Metabolites: PNU‐142300 and PNU‐142586 on the Development of Linezolid‐Induced Thrombocytopenia in Adult Patients. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.70124

BibTeX
@article{Sakurai2025,
  author = {Sakurai, Norihiro and Kawaguchi, Hiroshi and Matsui, Toya and Nishiura, Hironobu and Kobayashi, Kazuhiro and Imoto, Waki and Shibata, Wataru and Nakamura, Yasutaka and Kakeya, Hiroshi},
  title = {Evaluating the Impact of Linezolid Metabolites: PNU‐142300 and PNU‐142586 on the Development of Linezolid‐Induced Thrombocytopenia in Adult Patients},
  journal = {The Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/jcph.70124}
}
Kostenlos starten →